Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib
| Class:Id | LiteratureReference:9713997 |
|---|
| _displayName | Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib |
|---|
| _timestamp | 2021-02-02 01:31:50 |
|---|
| author | [Person:9713995] Toyokawa, Gouji
[Person:9714000] Hirai, Fumihiko
[Person:9713991] Inamasu, Eiko
[Person:9713994] Yoshida, Tsukihisa
[Person:9713998] Nosaki, Kaname
[Person:9713993] Takenaka, Tomoyoshi
[Person:9713992] Yamaguchi, Masafumi
[Person:9713996] Seto, Takashi
[Person:9713989] Takenoyama, Mitsuhiro
[Person:9713999] Ichinose, Yukito |
|---|
| created | [InstanceEdit:9713990] Rothfels, Karen, 2021-02-02 |
|---|
| journal | J Thorac Oncol |
|---|
| pages | e86-7 |
|---|
| pubMedIdentifier | 25393798 |
|---|
| title | Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib |
|---|
| volume | 9 |
|---|
| year | 2014 |
|---|
| (literatureReference) | [DefinedSet:9700564] crizotinib resistant ALK mutants [plasma membrane] [Homo sapiens]
[FailedReaction:9700656] alectinib resistant ALK mutants don't bind alectinib [Homo sapiens]
[FailedReaction:9715357] crizotinib-resistant ALK mutants don't bind crizotinib [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib (9713997)
